The stock of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) is increasing on US charts this morning. When we last checked in current session, Longboard’s stock was up 202.82% to $18.26. The positive outcomes of a significant clinical trial preceded the spike in LBPH shares.
Today, Longboard has released good topline results (LP352) from the PACIFIC Study, which is examining bexicaserin. It is an oral, new 5-HT2C receptor superagonist that is extremely selective and may be the best in class for treating seizures brought on by a variety of developmental and epileptic encephalopathies (DEEs).
52 people with a DEE diagnosis, aged 12-65, were recruited at 34 study locations in the US and Australia as part of the ground-breaking PACIFIC Study, which assessed the pharmacokinetics, safety, tolerability, and effectiveness of oral bexicaserin. Diagnoses for participant DEEs included LGS, DS, and other DEEs that met eligibility requirements.
In the DS, LGS, and DEE Other groups, the median change in countable motor seizure frequency from baseline was a reduction of 72.1%, 48.1%, and 61.2%, respectively. This amounts to a 27.3% and 28.6%, respectively, placebo-adjusted decrease in the frequency of seizures in LGS and DEE Other.
After completing the PACIFIC research, all participants made the decision to sign up for the current 52-week open-label extension research. With the potential to reinvent the standard of treatment in DEEs, bexicaserin’s distinctive profile could develop into a therapeutically and commercially best-in-class solution, as these exciting results from the PACIFIC Study demonstrate.
Together with good safety and tolerability outcomes, a significant seizure reduction was observed in a variety of DEE syndromes with different etiologies. With this significant accomplishment, LBPH gets one step closer to bettering the lives of individuals and their families affected by these incurable illnesses.
For treating patients with severely refractory, treatment-resistant seizures, doctors are searching for alternatives that have less adverse effects, are easier to combine with current treatments, and are less burdensome. This is a novel and distinctive method for clinical development that will increase research’s reach throughout the DEE community.
